Rosacea is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Rosacea have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Rosacea compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rosacea overview
Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing; small red lines under the skin; a swollen nose; and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.
For a complete picture of PTSR and LoA scores for drugs in Rosacea, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.